Researchers conducted a large, Phase 3 clinical trial to test a new treatment combination for myelofibrosis, a type of bone marrow cancer. The study involved 252 adults at about 190 sites worldwide. They compared the standard drug ruxolitinib alone to ruxolitinib combined with an investigational drug called navitoclax. The main goal was to see if the combination could reduce spleen volume by at least 35% after 24 weeks. An enlarged spleen is a common and often painful problem for people with myelofibrosis.
The full results for this main goal, including how many people responded, have not been reported yet. Safety information, such as side effects or how many people stopped treatment, is also not available. This is an important step in research, but navitoclax is still an experimental drug and is not approved for use.
Because the detailed results are not public, it is too early to know if this combination is effective or safe. The trial design means participants taking the combination had a higher treatment burden than standard care. Readers should understand that this is a research update, not a proven new treatment. The findings will need careful review by experts and regulatory agencies before any conclusions can be drawn about its future use.